* We corrected the errors and inappropriateness of the original meta-analysis, when conducted the quantitative analysis. Supplementary table S4 General characteristics and main findings of the 31 meta-analyses of RCTs Reported N N N Type of Effect Concordance in Author Year Population Versus Outcome summary studies participants Cases metric model overlapped MA therapy effect (95%) Kidney diseases Fink ADDIN EN.CITE Nephrolithiasis Placebo/no Nephrolithiasis 2013 Thiazides 5 300 151 RR Random 0.52 (0.39, 0.69) patients treatment recurrence Fink ADDIN EN.CITE Nephrolithiasis Placebo/no Nephrolithiasis 2013 Citrates 4 197 90 RR Random 0.25 (0.14, 0.44) patients treatment recurrence Fink ADDIN EN.CITE Nephrolithiasis Placebo/no Nephrolithiasis 2013 Allopurinol 2 152 78 RR Random 0.59 (0.42, 0.84) patients treatment recurrence All active Placebo/no -1.25 (-1.98, Wang59 2013 General SCr (mg/dL) 9 580 NA SMD Random therapy treatment All active Placebo/no Wang59 2013 General eGFR (ml/min/1.73m2) 3 218 NA SMD Fixed 0.41 (0.14, 0.68) therapy treatment
* We corrected the errors and inappropriateness of the original meta-analysis, when conducted the quantitative analysis. Supplementary table S4 General characteristics and main findings of the 31 meta-analyses of RCTs Author Year Population therapy Versus Outcome N studies N participants N Cases Type of metric Effect model Reported summary effect (95%) Concordance in overlapped MA Kidney diseases Fink ADDIN EN.CITE 2013 Nephrolithiasis patients Thiazides Placebo/no treatment Nephrolithiasis recurrence 5 300 151 RR Random 0.52 (0.39, 0.69) Fink ADDIN EN.CITE 2013 Nephrolithiasis patients Citrates Placebo/no treatment Nephrolithiasis recurrence 4 197 90 RR Random 0.25 (0.14, 0.44) Fink ADDIN EN.CITE 2013 Nephrolithiasis patients Allopurinol Placebo/no treatment Nephrolithiasis recurrence 2 152 78 RR Random 0.59 (0.42, 0.84) Wang59 2013 General All active therapy Placebo/no treatment SCr (mg/dL) 9 580 NA SMD Random -1.25 (-1.98, Wang59 2013 General All active therapy Placebo/no treatment eGFR (ml/min/1.73m2) 3 218 NA SMD Fixed 0.41 (0.14, 0.68)
Supplementary%20material_v7%20-%20Final-2.docx